Scienture Holdings rises on launch of opioid overdose antidote Rezenopy

Scienture Holdings

06/03/2025 12:59

** Shares of specialty pharma firm Scienture Holdings SCNX.O rise ~60% to $3.55 premarket

** SCNX says it is launching Rezenopy nasal spray 10mg, an opioid overdose emergency drug, through a collaboration with Kindeva Drug Delivery L.P.

** Kindeva will manufacture and supply Rezenopy, while SCNX will own the marketing application and be responsible for sales, marketing, and distribution in the U.S.

** Rezenopy is the most potent version of naloxone HCl available in the market, co says

** SCNX gained 81.7% in 2024

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))